INNOVENT BIO News

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 8 04:35 ET

INNOVENT BIO: CLARIFICATION ANNOUNCEMENT - GRANT OF RESTRICTED SHARES

Apr 3 09:37 ET

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE NEW DRUG APPLICATION AND GRANTED PRIORITY REVIEW DESIGNATION FOR SINTILIMAB COMBINATION WITH FRUQUINTINIB FOR THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER

Apr 2 00:25 ET

INNOVENT BIO: GRANT OF SHARE OPTIONS AND NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO DIRECTORS AND GRANT OF RESTRICTED SHARES

Mar 24 06:28 ET

INNOVENT BIO: PROPOSED ADOPTION OF THE NEW MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY

Mar 20 09:41 ET

INNOVENT BIO: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

Mar 20 06:30 ET

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 6 09:40 ET

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE SECOND NEW DRUG APPLICATION FOR TALETRECTINIB (ROS1 INHIBITOR)

Mar 4 18:30 ET

INNOVENT BIO: DATE OF BOARD MEETING

Feb 29 05:09 ET

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE PHASE 3 CLINICAL STUDY OF IBI311 MET THE PRIMARY ENDPOINT IN TREATING THYROID EYE DISEASE

Feb 19 18:30 ET

INNOVENT BIO: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION

Feb 9 06:08 ET

INNOVENT BIO: APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE

Feb 9 06:01 ET

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTED THE FIRST NEW DRUG APPLICATION FOR MAZDUTIDE FOR CHRONIC WEIGHT MANAGEMENT

Feb 7 03:30 ET

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Feb 6 05:11 ET

INNOVENT BIO: INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY''S PRODUCT REVENUE IN THE FOURTH QUARTER OF 2023

Feb 6 04:19 ET

INNOVENT BIO: RETIREMENT OF CHIEF FINANCIAL OFFICER AND APPOINTMENT OF NEW CHIEF FINANCIAL OFFICER

Feb 5 03:30 ET

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - THE FIRST PHASE 3 CLINICAL TRIAL OF MAZDUTIDE IN CHINESE ADULTS WITH OVERWEIGHT OR OBESITY MET THE PRIMARY AND ALL KEY SECONDARY ENDPOINTS

Jan 8 18:30 ET

INNOVENT BIO: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

Jan 5 09:55 ET

INNOVENT BIO: VOLUNTARY ANNOUNCEMENT - INCLUSION IN THE CHINA NATIONAL REIMBURSEMENT DRUG LIST (2023 VERSION) OF TYVYT''S SEVENTH INDICATION AND BYVASDA''S EIGHTH INDICATION

Dec 12, 2023 23:01 ET

INNOVENT BIO: GRANT OF SHARE OPTIONS AND GRANT OF RESTRICTED SHARES

Dec 7, 2023 09:47 ET